



SAFETY DATA SHEET

Revision date: 31-Mar-2015

Version: 2.0

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Paromomycin Sulfate Tablets

Trade Name: GABBRORAL
Synonyms: Aminosidine Sulfate Tablets
Chemical Family: Aminoglycoside

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

EU Classification:

EU Indication of danger: Not classified

Label Elements

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards

Australian Hazard Classification (NOHSC):

No data available
Non-Hazardous Substance. Non-Dangerous Goods.

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

SAFETY DATA SHEET

Material Name: Paromomycin Sulfate Tablets
Revision date: 31-Mar-2015

Page 2 of 8
Version: 2.0

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Paromomycin sulfate	1263-89-4	215-031-7	Not Listed	Not Listed	75-80
Maize starch	9005-25-8	232-679-6	Not Listed	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	Not Listed	*
Magnesium stearate	557-04-0	209-150-3	Not Listed	Not Listed	*

Additional Information:

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

SAFETY DATA SHEET

Material Name: Paromomycin Sulfate Tablets
Revision date: 31-Mar-2015

Page 3 of 8
Version: 2.0

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Maize starch

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Czech Republic OEL - TWA	4.0 mg/m ³
Greece OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	5 mg/m ³
	10 mg/m ³
	4 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	4 mg/m ³
Spain OEL - TWA	10 mg/m ³
Switzerland OEL - TWAs	3 mg/m ³

Colloidal silicon dioxide

Australia TWA	2 mg/m ³
Austria OEL - MAKs	4 mg/m ³
	0.3 mg/m ³
Czech Republic OEL - TWA	0.1 mg/m ³
	4.0 mg/m ³
Estonia OEL - TWA	2 mg/m ³
Finland OEL - TWA	5 mg/m ³
Germany - TRGS 900 - TWAs	4 mg/m ³
Germany (DFG) - MAK	4 mg/m ³

SAFETY DATA SHEET

Material Name: Paromomycin Sulfate Tablets
Revision date: 31-Mar-2015

Page 4 of 8
Version: 2.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Ireland OEL - TWAs	6 mg/m ³ 2.4 mg/m ³
Latvia OEL - TWA	1 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf Listed
Slovakia OEL - TWA	4.0 mg/m ³
Switzerland OEL -TWAs	4 mg/m ³ 0.3 mg/m ³

Magnesium stearate

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Paromomycin sulfate

Pfizer Occupational Exposure Band (OEB): OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Tablets	Color:	White, cream colored
Odor:	No data available.	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Paromomycin sulfate
Predicted 7.4 Log D -11.023

Colloidal silicon dioxide

No data available

Magnesium stearate

No data available

Maize starch

No data available

Decomposition Temperature (°C): No data available.

SAFETY DATA SHEET

Material Name: Paromomycin Sulfate Tablets
Revision date: 31-Mar-2015

Page 5 of 8
Version: 2.0

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: No data available
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.
Long Term: Animal studies indicate that this material may cause adverse effects on the kidneys and nervous system.
Known Clinical Effects: Adverse effects associated with therapeutic use include abdominal cramping, nausea and diarrhea. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. The following effects are based on a chemically-related material: contact dermatitis, effects on hearing.

Acute Toxicity: (Species, Route, End Point, Dose)

Paromomycin sulfate

Rat Oral LD50 21,620 mg/kg
Mouse Oral LD50 23,500 mg/kg
Rat Intravenous LD50 181mg/kg
Rat Intramuscular LD50 1200mg/kg
Rat Subcutaneous LD 50 870

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg
Rat Inhalation LC50 > 2000 mg/m³

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

SAFETY DATA SHEET

Material Name: Paromomycin Sulfate Tablets
Revision date: 31-Mar-2015

Page 6 of 8
Version: 2.0

11. TOXICOLOGICAL INFORMATION

Paromomycin sulfate

3 Month(s)	Rabbit	Subcutaneous	60 mg/kg/day	LOAEL	Kidney
3 Month(s)	Rat	Subcutaneous	200 mg/kg/day	LOAEL	Kidney
3 Month(s)	Mouse	Subcutaneous	400 mg/kg/day	LOAEL	Kidney
3 Month(s)	Cat	Subcutaneous	50 mg/kg/day	LOAEL	Nervous System

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Paromomycin sulfate

Embryo / Fetal Development Rat Intramuscular 400 mg/kg/day NOAEL No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Paromomycin sulfate

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
In Vivo Micronucleus Mouse Negative
In Vitro Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative
In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Paromomycin sulfate

2 Year(s)	Rat	No route specified	Not carcinogenic
2 Year(s)	Dog	No route specified	Not carcinogenic

Carcinogen Status:

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Colloidal silicon dioxide

IARC:

Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview:

Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

Toxicity:

No data available

Persistence and Degradability:

No data available

Bio-accumulative Potential:

Partition Coefficient: (Method, pH, Endpoint, Value)

Paromomycin sulfate

Predicted 7.4 Log D -11.023

Mobility in Soil:

No data available

SAFETY DATA SHEET

Material Name: Paromomycin Sulfate Tablets
Revision date: 31-Mar-2015

Page 7 of 8
Version: 2.0

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

None required

Paromomycin sulfate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	215-031-7

Maize starch

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

Colloidal silicon dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Paromomycin Sulfate Tablets
Revision date: 31-Mar-2015

Page 8 of 8
Version: 2.0

15. REGULATORY INFORMATION

EU EINECS/ELINCS List	231-545-4
-----------------------	-----------

Magnesium stearate

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------

California Proposition 65	Not Listed
---------------------------	------------

Inventory - United States TSCA - Sect. 8(b)	Present
---	---------

Australia (AICS):	Present
-------------------	---------

EU EINECS/ELINCS List	209-150-3
-----------------------	-----------

16. OTHER INFORMATION

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.
Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients.

Revision date: 31-Mar-2015

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet